Cost Is a Barrier to Adherence — and Providers Can Help

You've evaluated your patient, confirmed moderate to severe vasomotor symptoms, reviewed the liver monitoring requirements, and decided that Veozah (Fezolinetant) is the right nonhormonal option. Then your patient calls from the pharmacy: "They said it's $700. I can't afford this."

This scenario plays out more often than it should. Veozah has a cash price of $550–$765 per month, and even with commercial insurance, copays can range from $30 to over $200 depending on the plan's tier placement and formulary restrictions. For a medication that treats a condition many patients already feel is dismissed or minimized, a high price tag is often the final straw that leads to abandonment — not of the pharmacy, but of treatment altogether.

The reality is that multiple savings programs exist for Veozah, and many patients qualify for significant cost reductions. The problem is that patients don't know about these programs, and the enrollment process often falls through the cracks between your office and the pharmacy counter. This guide is designed to give you and your team the tools to proactively address cost before it becomes an adherence barrier.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you set appropriate expectations and identify which patients need the most help.

Without Insurance

The wholesale acquisition cost (WAC) for Veozah 45 mg, 30 tablets, results in cash prices ranging from $550 to $765 per month depending on the pharmacy. This puts Veozah in the same price range as many specialty medications, despite being dispensed at retail pharmacies.

With Commercial Insurance

Most major commercial plans now include Veozah on their formularies, though coverage specifics vary significantly:

• Tier placement: Typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty)
• Prior authorization: Required by most plans. Common criteria include documented moderate to severe VMS, trial and failure of hormone therapy (if not contraindicated), and sometimes trial of Brisdelle.
• Step therapy: Some plans require patients to try a less expensive alternative first — usually HRT or Brisdelle — before approving Veozah
• Patient copay: Ranges from $30–$75 (Tier 3 with good coverage) to $150–$250+ (Tier 4 or high-deductible plans)

Medicare Part D

Some Medicare Part D plans cover Veozah. The 2025 Part D redesign capped out-of-pocket costs at $2,000 per year, which provides meaningful protection for patients on expensive brand medications. However, manufacturer copay cards are not valid for Medicare patients, so this population often faces higher out-of-pocket costs.

Uninsured Patients

Uninsured patients face the full cash price unless they can access patient assistance programs (detailed below). This population needs the most proactive support from your office.

Manufacturer Savings Programs

Veozah Savings Card (Commercial Insurance)

Astellas offers the Veozah Savings Card for commercially insured patients. Key details:

• First month: Eligible patients may pay as little as $0
• Monthly refills: As little as $30 per month
• Annual maximum: Up to $4,000 in copay assistance per calendar year
• If insurance claim is rejected: Assistance may be limited to $1,250 for the first two months
• Enrollment: veozah.com/savings or veozahsupportsolutions.com
• Not valid for: Medicare, Medicaid, Tricare, VA, or other government-funded insurance

This is the single most impactful savings tool for commercially insured patients. With the savings card, a patient who would otherwise pay $150–$250/month in copays can reduce their cost to $30/month. The problem is that many patients never learn about it.

How to Integrate the Savings Card into Your Workflow

• Mention it at the point of prescribing. When you write the Veozah prescription, tell the patient: "There's a savings card from the manufacturer that can bring your monthly cost down to about $30. Here's how to sign up."
• Have your staff enroll patients. If your practice has patient navigators, prior auth specialists, or dedicated pharmacy liaisons, make Veozah savings card enrollment part of the standard workflow for new Veozah prescriptions.
• Include the savings card info in after-visit summaries. Add the enrollment URL (veozah.com/savings) to your standard patient handout for Veozah.

Veozah Support Solutions (Uninsured/Underinsured)

Astellas also offers Veozah Support Solutions (veozahsupportsolutions.com) for patients who are uninsured or underinsured. This program can help connect patients with:

• Free or reduced-cost medication
• Insurance navigation assistance
• Help with prior authorizations and appeals

Encourage uninsured patients to call the support line or visit the website. Your office can also call on the patient's behalf to initiate enrollment.

Coupon and Discount Card Programs

For patients who don't qualify for the manufacturer savings card — or who need additional help — third-party discount programs can offer meaningful savings.

Pharmacy Discount Cards

Several pharmacy discount card providers include Veozah in their programs:

• SingleCare — singlecare.com/prescription/veozah
• GoodRx — goodrx.com/veozah
• BuzzRx — buzzrx.com/veozah/coupon
• RxSaver — rxsaver.com/drugs/veozah/coupons
• Optum Perks — perks.optum.com/drug/veozah

Discount card pricing for Veozah typically ranges from $500–$700 — a modest discount from cash price, but potentially meaningful compared to uninsured retail pricing. These cards are most useful for patients who are between insurance plans or who have very high deductibles and need to bridge the gap before their deductible is met.

Important note for your staff: Discount cards cannot be combined with insurance copays or manufacturer copay cards. They are cash-price alternatives.

Generic Alternatives and Therapeutic Substitution

Generic Veozah

There is no generic Fezolinetant available as of 2026. Veozah is under patent protection by Astellas Pharma, and a generic version is not expected in the near term.

Therapeutic Alternatives

When cost is the primary barrier, consider whether a therapeutic alternative might be appropriate for your patient:

• Brisdelle (Paroxetine mesylate 7.5 mg): The only other FDA-approved nonhormonal treatment for VMS. Significantly less expensive than Veozah and does not require liver monitoring. Trade-offs include SSRI side effects (drowsiness, weight changes) and generally more modest efficacy for hot flash reduction.
• Lynkuet (Elinzanetant): A dual NK1/NK3 receptor antagonist approved in October 2025. Also brand-only and similarly priced, but may be covered differently by some insurance plans. Worth checking if Veozah coverage is denied.
• Hormone replacement therapy: When not contraindicated, HRT remains the most effective and generally most affordable treatment for VMS. Generic oral estradiol is available for under $20/month in many cases.
• Off-label options: Effexor XR (Venlafaxine), Neurontin (Gabapentin), and Catapres (Clonidine) are available as generics at significantly lower costs, though efficacy for VMS varies and these are off-label uses.

For a comprehensive comparison, refer patients to our Veozah alternatives guide.

Building Cost Conversations into Your Clinical Workflow

The most effective way to prevent cost-related non-adherence is to address it before the patient leaves your office. Here's how to integrate cost discussions into your Veozah prescribing workflow:

1. Screen for Cost Barriers at the Point of Prescribing

A simple question: "Do you have any concerns about the cost of this medication?" opens the door. Many patients won't bring up cost on their own because they feel embarrassed or don't want to seem like they're questioning your clinical judgment. Asking proactively normalizes the conversation.

2. Standardize Your Veozah Onboarding

Create a checklist for every new Veozah prescription:

1. Verify insurance coverage and tier status
2. Submit prior authorization (if required)
3. Enroll patient in Veozah Savings Card (commercially insured) or Veozah Support Solutions (uninsured/underinsured)
4. Confirm patient has a pharmacy that stocks Veozah — use Medfinder for Providers to check availability
5. Schedule baseline liver labs and month 1 follow-up

3. Designate a Team Member for Savings Program Enrollment

Whether it's an MA, nurse, front desk staff, or patient navigator, assign someone to handle savings card enrollment as a standard part of the prescription workflow. This takes 5 minutes but can save your patient hundreds of dollars per month.

4. Follow Up on Fill Status

Check in with the patient at their month-1 liver monitoring visit: "Were you able to fill your Veozah prescription? What did you end up paying?" This allows you to catch problems early and troubleshoot cost issues before the patient quietly stops treatment.

5. Document Cost Discussions

Note in the chart that you discussed cost, what savings programs were offered, and the patient's out-of-pocket cost. This is valuable for continuity of care and for supporting appeals if insurance denies coverage.

Additional Resources for Providers

• Veozah Support Solutions: veozahsupportsolutions.com — manufacturer support for coverage, cost, and access questions
• NeedyMeds: needymeds.org — comprehensive database of patient assistance programs
• RxAssist: rxassist.org — patient assistance program directory
• RxHope: rxhope.com — connects patients with manufacturer assistance programs
• Medfinder for Providers: medfinder.com/providers — help your patients find pharmacies with Veozah in stock

Final Thoughts

Cost should not be the reason your patient stops taking a medication that's working. With Veozah, the savings infrastructure exists — manufacturer copay cards, patient assistance programs, and discount cards can bring the monthly cost from $700+ down to $30 or even $0 for many patients. The gap is awareness and enrollment, and that's where your practice can make a measurable difference.

By building cost conversations and savings program enrollment into your standard prescribing workflow, you're not just writing a prescription — you're ensuring your patient can actually fill it, afford it, and stay on it. That's the difference between a prescription and a treatment.

For more clinical resources on Veozah, including shortage and supply updates and guidance on helping patients find Veozah in stock, visit our provider resource library at medfinder.com/providers.